Cassava Sciences | PTIE - Ebitda


Cassava Sciences reported $-11.73M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Abbott USD 2.43B 844M Mar/2026
Amgen USD 5.14B 775M Dec/2025
Biogen USD 649.7M 76.5M Mar/2026
Cara Therapeutics USD -2.39M 3.16M Mar/2025
Cassava Sciences USD -11.73M 33.44M Sep/2025
Eisai JPY -335M 30.43B Mar/2026
Eli Lilly USD 12.14B 4.26B Dec/2025
Geron USD -21.29M 11.82M Dec/2025
J&J USD 8.27B 1.08B Mar/2026
Merck USD 6.3B 2.09B Dec/2025
Novartis USD 5.3B 530M Mar/2026
Novavax USD 19.36M 190.79M Dec/2025
Pfizer USD 5.99B 5.23B Mar/2026
Roche Holding CHF 12.68B 2.36B Jun/2024